AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Neutrophil Inhibitory Factor Limits Parasite Fecundity.(Brief Article)
2001 JUL 11 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer - Vaccination of hamsters with neutrophil inhibitory factor (NIF), a protein isolated from hookworms of the genus Ancylostoma, does not reduce hookworm burden but does limit the ability of the worms to reproduce, according to a new report in Parasite Immunology.
"Historically, NIF was serendipitously isolated from whole worm extracts during a search for novel anti-hemostatic agents, and little is known of its source or biological significance to the parasite," wrote F. Ali and colleagues in England.
They purified A. ceylanicum recombinant NIF, expressed in its active form in Pichia pastoris and tested the vaccine in hamsters that were challenged with A. ceylanicum.
Although the NIF vaccine stimulated NIF-specific antibodies, it did not reduce hookworm burden or hematocrit values in the infected animals, reported Ali and coworkers. It did, however, cause a significant reduction in worm fecundity (85.8% by day 21 postinfection), suggesting that it could protect against subsequent transmission ("Vaccination with neutrophil inhibitory factor reduces the fecundity of the hookworm Ancylostoma ceylanicum," Parasite Immunol, 2001;23(5):237-249.
"These data indicate that targeted ...
- Neutrophil Inhibitory Factor Limits Parasite Fecundity.
- Newspaper article from: TB & Outbreaks Week July 10, 2001 700+ words
...staff medical writer - Vaccination of hamsters with neutrophil inhibitory factor (NIF), a protein isolated from hookworms of...against subsequent transmission ("Vaccination with neutrophil inhibitory factor reduces the fecundity of the hookworm Ancylostoma...
- Corvas Announces Termination of Oral Thrombin Program With Schering-Plough
- Press release article from: PR Newswire August 14, 1998 700+ words
...scheduled to enter Phase II later this year and NIF (neutrophil inhibitory factor) being developed by Pfizer Inc. for ischemic...has a strategic alliance with Pfizer Inc. to develop neutrophil inhibitory factor (NIF) as a possible stroke therapy, and alliances...
- PFIZER RETURNS RNIF PRODUCT TO CORVAS; DRUG'S FUTURE UNKNOWN.(rights to...
- Magazine article from: BIOWORLD Today Huggett, Brady June 18, 2002 700+ words
...Pfizer, of New York, completed its analysis of the Phase IIb trial it conducted with UK-279,276 (formerly neutrophil inhibitory factor, or rNIF) and saw that the product had no effect on recovery in acute ischemic stroke patients, nor...
- Corvas Receives Notice From Pfizer of Completion of Phase I Clinical Trial on...
- Press release article from: PR Newswire July 6, 1998 700+ words
...Nasdaq: CVAS) today announced that Pfizer Inc. (NYSE: PFE) has completed a Phase Ia clinical trial of neutrophil inhibitory factor (NIF), an anti-inflammatory drug candidate discovered by Corvas intended for use in ischemic stroke...
- ABGENIX: ABX-IL8 FAILS AGAIN, NEW DEAL SIGNED WITH CORVAS.(Brief Article)
- Magazine article from: BIOWORLD Today Osborne, Randall May 15, 2002 700+ words
...Pfizer Inc., of New York, disclosed that preliminary analysis of a Phase IIb study of UK-279,276, a neutrophil inhibitory factor, in ischemic stroke showed that it failed to meet its primary endpoints and therefore did not support...
- CORVAS CUTS 40 PERCENT OF STAFF, FOCUSES ON LATE- STAGE PRODUCTS.(Brief Article)
- Magazine article from: BIOWORLD Today Coghill, Kim July 24, 2002 700+ words
...recent developments related to a deal with New York- based Pfizer Inc. Pfizer last month returned Corvas' neutrophil inhibitory factor (rNIF) after the product, also referred to as UK- 279,276, failed to show activity in acute ischemic...
- CORVAS COMPLETES FIRST PART OF $15M FINANCING.(Brief Article)
- Magazine article from: BIOWORLD Today Pihl-Carey, Karen August 23, 1999 700+ words
...resulting from abnormal blood clot formulation or thrombosis. Its other advanced-stage product is recombinant neutrophil inhibitory factor (rNIF), which is in a Phase IIa trial for patients with acute ischemic stroke. That product is partnered...
- CORVAS COMPLETES FIRST PART OF $15M FINANCING.
- Magazine article from: BIOWORLD Today Pihl-Carey, Karen August 23, 1999 700+ words
...resulting from abnormal blood clot formulation or thrombosis. Its other advanced-stage product is recombinant neutrophil inhibitory factor (rNIF), which is in a Phase IIa trial for patients with acute ischemic stroke. That product is partnered...